{
  "api_version": "1",
  "request": {
    "url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Olanzapine+10+MG",
    "query": {
      "intervention": "Olanzapine 10 MG"
    },
    "page_size": 10
  },
  "pagination": {
    "page": 1,
    "page_size": 10,
    "total_count": 41,
    "total_pages": 5,
    "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Olanzapine+10+MG&page=2&page_size=10",
    "previous_page_url": null
  },
  "source": "remote",
  "last_synced_at": "2026-09-28T02:45:21.648Z",
  "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.",
  "notes": [
    "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.",
    "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.",
    "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees."
  ],
  "trials": [
    {
      "nct_id": "NCT02804568",
      "title": "A Phase 1 Safety Study in Adults With Schizophrenia",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Schizophrenia"
      ],
      "interventions": [
        {
          "name": "ALKS 3831",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Alkermes, Inc.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "55 Years",
        "sex": "ALL",
        "summary": "18 Years to 55 Years"
      },
      "enrollment_count": 42,
      "start_date": "2016-06",
      "completion_date": "2016-08",
      "has_results": false,
      "last_update_posted_date": "2016-09-22",
      "last_synced_at": "2026-09-28T02:45:21.648Z",
      "location_count": 3,
      "location_summary": "Little Rock, Arkansas • Clementon, New Jersey • Dayton, Ohio",
      "locations": [
        {
          "city": "Little Rock",
          "state": "Arkansas"
        },
        {
          "city": "Clementon",
          "state": "New Jersey"
        },
        {
          "city": "Dayton",
          "state": "Ohio"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02804568"
    },
    {
      "nct_id": "NCT00636896",
      "title": "Effects of Modafinil on Olanzapine Weight Gain",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "NA"
      ],
      "conditions": [
        "Weight Gain"
      ],
      "interventions": [
        {
          "name": "Olanzapine plus modafinil",
          "type": "DRUG"
        },
        {
          "name": "Olanzapine plus placebo",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Neuropsychiatric Research Institute, Fargo, North Dakota",
      "sponsor_class": "OTHER",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "60 Years",
        "sex": "ALL",
        "summary": "18 Years to 60 Years"
      },
      "enrollment_count": 50,
      "start_date": "2006-07",
      "completion_date": "2007-08",
      "has_results": false,
      "last_update_posted_date": "2008-03-17",
      "last_synced_at": "2026-09-28T02:45:21.648Z",
      "location_count": 1,
      "location_summary": "Fargo, North Dakota",
      "locations": [
        {
          "city": "Fargo",
          "state": "North Dakota"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00636896"
    },
    {
      "nct_id": "NCT05547100",
      "title": "Study of the Breast Milk Pharmacokinetics of Olanzapine and Samidorphan",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Focus of Study is on Healthy Lactating Women"
      ],
      "interventions": [
        {
          "name": "LYBALVI",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Alkermes, Inc.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "45 Years",
        "sex": "FEMALE",
        "summary": "18 Years to 45 Years · Female only"
      },
      "enrollment_count": 12,
      "start_date": "2022-09-14",
      "completion_date": "2022-11-19",
      "has_results": false,
      "last_update_posted_date": "2023-02-10",
      "last_synced_at": "2026-09-28T02:45:21.648Z",
      "location_count": 1,
      "location_summary": "Las Vegas, Nevada",
      "locations": [
        {
          "city": "Las Vegas",
          "state": "Nevada"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT05547100"
    },
    {
      "nct_id": "NCT01234779",
      "title": "A Study of RO4917838 (Bitopertin) in Patients With Acute Exacerbation of Schizophrenia",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Schizophrenia"
      ],
      "interventions": [
        {
          "name": "bitopertin [RO4917838]",
          "type": "DRUG"
        },
        {
          "name": "olanzapine",
          "type": "DRUG"
        },
        {
          "name": "placebo",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Hoffmann-La Roche",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "65 Years",
        "sex": "ALL",
        "summary": "18 Years to 65 Years"
      },
      "enrollment_count": 301,
      "start_date": "2011-02",
      "completion_date": "2012-09",
      "has_results": false,
      "last_update_posted_date": "2016-11-02",
      "last_synced_at": "2026-09-28T02:45:21.648Z",
      "location_count": 19,
      "location_summary": "Little Rock, Arkansas • Cerritos, California • Oceanside, California + 16 more",
      "locations": [
        {
          "city": "Little Rock",
          "state": "Arkansas"
        },
        {
          "city": "Cerritos",
          "state": "California"
        },
        {
          "city": "Oceanside",
          "state": "California"
        },
        {
          "city": "Pico Rivera",
          "state": "California"
        },
        {
          "city": "San Diego",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01234779"
    },
    {
      "nct_id": "NCT00320489",
      "title": "Olanzapine Pamoate Depot Versus Oral Olanzapine on Treatment Outcomes in Outpatients With Schizophrenia",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Schizophrenia"
      ],
      "interventions": [
        {
          "name": "olanzapine",
          "type": "DRUG"
        },
        {
          "name": "olanzapine pamoate depot",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Eli Lilly and Company",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "65 Years",
        "sex": "ALL",
        "summary": "18 Years to 65 Years"
      },
      "enrollment_count": 524,
      "start_date": "2006-04",
      "completion_date": "2009-09",
      "has_results": true,
      "last_update_posted_date": "2012-01-23",
      "last_synced_at": "2026-09-28T02:45:21.648Z",
      "location_count": 13,
      "location_summary": "Escondido, California • National City, California • Orange, California + 10 more",
      "locations": [
        {
          "city": "Escondido",
          "state": "California"
        },
        {
          "city": "National City",
          "state": "California"
        },
        {
          "city": "Orange",
          "state": "California"
        },
        {
          "city": "San Diego",
          "state": "California"
        },
        {
          "city": "Washington D.C.",
          "state": "District of Columbia"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00320489"
    },
    {
      "nct_id": "NCT04987658",
      "title": "Phase 1 Study of OLZ/SAM in Pediatric Subjects With Bipolar I Disorder",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Bipolar I Disorder"
      ],
      "interventions": [
        {
          "name": "OLZ/SAM",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Alkermes, Inc.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "10 Years",
        "maximum_age": "12 Years",
        "sex": "ALL",
        "summary": "10 Years to 12 Years"
      },
      "enrollment_count": 7,
      "start_date": "2021-07-22",
      "completion_date": "2023-08-11",
      "has_results": false,
      "last_update_posted_date": "2023-11-22",
      "last_synced_at": "2026-09-28T02:45:21.648Z",
      "location_count": 2,
      "location_summary": "Decatur, Georgia • Cincinnati, Ohio",
      "locations": [
        {
          "city": "Decatur",
          "state": "Georgia"
        },
        {
          "city": "Cincinnati",
          "state": "Ohio"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT04987658"
    },
    {
      "nct_id": "NCT05857566",
      "title": "Effect of RDX-002 on Postprandial Triglycerides in Subjects Treated With Olanzapine",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Drug-induced Weight Gain"
      ],
      "interventions": [
        {
          "name": "RDX-002",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Response Pharmaceuticals",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "50 Years",
        "sex": "ALL",
        "summary": "18 Years to 50 Years"
      },
      "enrollment_count": 24,
      "start_date": "2023-05-16",
      "completion_date": "2023-09-13",
      "has_results": false,
      "last_update_posted_date": "2023-11-18",
      "last_synced_at": "2026-09-28T02:45:21.648Z",
      "location_count": 1,
      "location_summary": "Saint Paul, Minnesota",
      "locations": [
        {
          "city": "Saint Paul",
          "state": "Minnesota"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT05857566"
    },
    {
      "nct_id": "NCT01207414",
      "title": "Switching to Iloperidone From Other Antipsychotics in Schizophrenia",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE4"
      ],
      "conditions": [
        "Schizophrenia"
      ],
      "interventions": [
        {
          "name": "iloperidone",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Novartis",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "64 Years",
        "sex": "ALL",
        "summary": "18 Years to 64 Years"
      },
      "enrollment_count": 501,
      "start_date": "2010-08",
      "completion_date": "2012-01",
      "has_results": true,
      "last_update_posted_date": "2013-03-15",
      "last_synced_at": "2026-09-28T02:45:21.648Z",
      "location_count": 59,
      "location_summary": "Birmingham, Alabama • Cerritos, California • Costa Mesa, California + 46 more",
      "locations": [
        {
          "city": "Birmingham",
          "state": "Alabama"
        },
        {
          "city": "Cerritos",
          "state": "California"
        },
        {
          "city": "Costa Mesa",
          "state": "California"
        },
        {
          "city": "Garden Grove",
          "state": "California"
        },
        {
          "city": "Long Beach",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01207414"
    },
    {
      "nct_id": "NCT03230864",
      "title": "Efficacy of Lu AF35700 in Patients With Early-in-disease or Late-in-disease Treatment-resistant Schizophrenia",
      "overall_status": "TERMINATED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Treatment-resistant Schizophrenia"
      ],
      "interventions": [
        {
          "name": "Lu AF35700",
          "type": "DRUG"
        },
        {
          "name": "Risperidone",
          "type": "DRUG"
        },
        {
          "name": "Olanzapine",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "H. Lundbeck A/S",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 119,
      "start_date": "2017-07-20",
      "completion_date": "2019-02-05",
      "has_results": true,
      "last_update_posted_date": "2020-01-21",
      "last_synced_at": "2026-09-28T02:45:21.648Z",
      "location_count": 10,
      "location_summary": "San Diego, California • Atlanta, Georgia • Chicago, Illinois + 7 more",
      "locations": [
        {
          "city": "San Diego",
          "state": "California"
        },
        {
          "city": "Atlanta",
          "state": "Georgia"
        },
        {
          "city": "Chicago",
          "state": "Illinois"
        },
        {
          "city": "Fall River",
          "state": "Massachusetts"
        },
        {
          "city": "Worcester",
          "state": "Massachusetts"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03230864"
    },
    {
      "nct_id": "NCT00203307",
      "title": "A Research Study Examining the Use of Olanzapine for the Prevention of Migraine",
      "overall_status": "TERMINATED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "NA"
      ],
      "conditions": [
        "Migraine"
      ],
      "interventions": [
        {
          "name": "Olanzapine during first intervention period and placebo during second intervention period",
          "type": "DRUG"
        },
        {
          "name": "Placebo during first intervention period, then olanzapine during second intervention period",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Thomas Jefferson University",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "65 Years",
        "sex": "ALL",
        "summary": "18 Years to 65 Years"
      },
      "enrollment_count": 3,
      "start_date": "2004-05",
      "completion_date": "2006-06",
      "has_results": true,
      "last_update_posted_date": "2011-08-25",
      "last_synced_at": "2026-09-28T02:45:21.648Z",
      "location_count": 1,
      "location_summary": "Philadelphia, Pennsylvania",
      "locations": [
        {
          "city": "Philadelphia",
          "state": "Pennsylvania"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00203307"
    }
  ]
}